

Lymphoma study Standard 4.6

John Azar, M.D.

Commission on Cancer Standard 4.6

- Each calendar year, the Cancer Committee designates a physician member to complete an in-depth analysis to assess and verify that cancer program patients are evaluated and treated according to evidence based national treatment guidelines.
- Results are presented to the cancer committee, and documented in cancer committee minutes.

- The analysis must aim to determine if the diagnostic evaluation is adequate and the treatment plan is concordant with the recognized guidelines.
- Any problems identified in the diagnostic evaluation or treatment planning process may serve as a source for performance improvement.

Lymphoma Patients 2014-2015

Histology

- Total cases:31
- High Grade (e.g. DLBCL):11
- Low Grade (e.g. Follicular):13
- Hodgkins Lymphoma : 4
- T Cell Lymphoma : 1
- Others (n/a) : 2

Treatment

- 18/31 were treated
- 10 eligible for treatment declined or transferred

- Of the High Grade total of 11 patients, 6 received R-CHOP., 5 N/A.
- Of the Low Grade total of 13 patients, 8 received B-R, 5 were N/A.
- Of the Hodgkins Lymphoma total of 4 patients , all received ABVD.
- One T-Cell Lymphoma, which received CHOP.
- Compliance with Guidelines= 100%

WORKUP

ESSENTIAL:

- Physical exam: attention to node-bearing areas, including Waldeyer's ring, and to size of liver and spleen
- Performance status
- B symptoms
- CBC, differential, platelets
- LDH
- Beta-2-microglobulin
- Comprehensive metabolic panel
- Hepatitis B testing^h
- Chest/abdominal/pelvic (C/A/P) CT with contrast of diagnostic quality and/or whole-body PET/CT scan (PET/CT scan essential if RT for stage I, II disease planned)
- Bone marrow biopsy + aspirate to document clinical stage I-II diseaseⁱ
- Pregnancy testing in women of child-bearing age (if chemotherapy or RT planned)

USEFUL IN SELECTED CASES:

- Echocardiogram or MUGA scan if anthracycline or anthracenedione-based regimen is indicated
- Neck CT with contrast
- Uric acid
- Discussion of fertility issues and sperm banking
- SPEP and/or quantitative immunoglobulin levels
- Hepatitis C testing

Lymphoma Diagnosis

- CT studies- 29/29
- Compliance = 100%
- Bone Marrow studies (stage 1-2) 2/2
- Compliance = 100%
- Beta 2 Microglobulin 4/13
- Compliance = 31%

- Total of patients receiving Rituxan = 15
- 5/15 tested for hepatitis
- Compliance = 30%